BioCentury
ARTICLE | Company News

Intrexon, Oragenics deal

August 3, 2015 7:00 AM UTC

Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically modified Lactococcus lactis platform, including AG013, to treat oral mucositis (OM) and other diseases of the oral cavity, throat and esophagus. The deal excludes the use of the products for the prophylaxis of cancer. ...